LEGN CEO Resigns as J&J Bispecifics Challenge CAR-T

Legend Biotech (NASDAQ: LEGN) announced on July 27 that CEO Ying Huang, Ph.D., has stepped down effective July 24, 2026, after seven years leading the company. The board appointed Alan Bash, currently president of the CARVYKTI Business Unit, as interim CEO. A search for a permanent successor is underway.

Huang’s resignation “was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices,” Legend said in an SEC filing. He will remain as an advisor through August. Legend shares closed at $19.27 on July 25, market cap near $3.6 billion.

The Timing Is the Story

The resignation came the same week J&J reported Q2 2026 earnings that included CARVYKTI’s largest quarter yet. Worldwide CARVYKTI sales hit $657 million in Q2, up 49.4% year-over-year, bringing first-half revenue to $1.25 billion. J&J and Legend co-develop the BCMA-directed CAR-T therapy, which is one of only two approved CAR-T products in multiple myeloma alongside BMS/2seventy bio’s Abecma.

But the same week, J&J also reported Phase 3 data from its bispecific antibody combination that directly threatens CAR-T’s position. The MonumenTAL-6 trial showed Tecvayli (teclistamab) plus Talvey (talquetamab) delivered an 89% reduction in the risk of disease progression or death in heavily pre-treated relapsed myeloma patients. Bispecifics are off-the-shelf injections. CAR-T requires apheresis, weeks of manufacturing, and specialized treatment centers.

Why the CEO Change Matters

Bash joined Legend in 2024 to run the CARVYKTI commercial unit, four years after Huang was elevated from CFO to CEO when founder Fangliang Zhang stepped aside amid a customs investigation in China that was later closed without charges.

The governance concern is the lack of a permanent CEO at a company facing a structural competitive shift. CAR-T therapies like CARVYKTI require complex logistics: patient cells are extracted, sent to a manufacturing facility, modified, and reinfused weeks later. Bispecific antibodies are administered in community oncology clinics without any of that infrastructure.

Legend’s Q1 2026 CARVYKTI sales were $597 million, up 62% year-over-year. The growth is real. The question is whether the growth rate holds as bispecifics expand.

What to Watch

The permanent CEO search is the immediate catalyst. A commercial leader suggests the board believes CARVYKTI’s franchise can be defended through execution. A scientific leader suggests a pivot toward earlier-stage pipeline assets.

Second, Legend’s partner J&J reported Q2 earnings on July 15, the same week the bispecific data landed. CARVYKTI’s $657 million quarter beat expectations, but the stock fell 10% as investors digested the bispecific threat. The J&J bispecific franchise is growing fast too: Tecvayli hit $260 million in Q2 (up 56.5%), and Talvey reached $174 million (up 63.3%). Both are smaller than CARVYKTI but growing faster off a lower base.

Third, watch the competitive dynamic between J&J Tecvayli/Talvey bispecifics in myeloma. Gilead’s anito-cel, another BCMA CAR-T, faces a PDUFA decision that will further define the CAR-T field. If bispecifics continue to demonstrate efficacy rivaling CAR-T with far simpler logistics, the entire CAR-T manufacturing model in myeloma comes under pressure, and Legend’s next CEO inherits that problem.

For now, Legend is a company with a growing product, a departing CEO, and a competitive field that is shifting beneath its feet. The interim CEO keeps the lights on. The permanent one will decide what Legend becomes.

Source: Legend Biotech CEO transition press release, July 27, 2026

What It Means for the Trade

The trade is a governance vacuum colliding with a structural competitive threat, and the market prices both at $19.27. CARVYKTI’s fundamentals are still strong — $657 million in Q2, up 49.4%, first-half revenue at $1.25 billion — but the MonumenTAL-6 readout (89% risk reduction from the Tecvayli-Talvey bispecific combination) is the kind of data that re-rates a franchise’s terminal value, not its next quarter. Bispecifics win on physics: an off-the-shelf injection versus apheresis, manufacturing, and reinfusion means community-clinic deployment. The near-term catalyst is the permanent CEO hire: Alan Bash is a commercial operator running the CARVYKTI unit, and if the board keeps that profile, it is a defend-the-franchise mandate; a scientific hire signals retreat to the earlier pipeline.

Mechanism and Market Context

CARVYKTI is a BCMA-directed CAR-T: a patient’s own T cells are engineered to target B-cell maturation antigen on myeloma cells, expanded, and reinfused as a one-time, living drug with deep, durable responses in heavily pretreated patients. Tecvayli and Talvey are bispecific antibodies — one BCMA-targeted, one GPRC5D-targeted — that bridge T cells to myeloma cells without any cell engineering, tradeable for off-the-shelf convenience but requiring continuous dosing to sustain the effect. That trade defines the field: CAR-T holds the depth-of-response high ground, bispecifics hold the access and convenience high ground, and MonumenTAL-6’s combination data suggests the convenience gap may not cost efficacy. Legend’s leverage is that CARVYKTI is one of only two approved myeloma CAR-Ts (with BMS/2seventy’s Abecma), and Gilead’s anito-cel PDUFA will add a third competitor to the same niche.

Risks and What Could Go Wrong

1. A prolonged CEO search or a transition stumble compounds the credibility discount on a $3.6 billion company with a single commercial asset.
2. If bispecific combinations keep matching CAR-T efficacy at community-clinic convenience, line-positioning pushes CAR-T later and later, compressing CARVYKTI’s growth rate from the front.
3. Manufacturing-slot scarcity caps near-term CAR-T revenue no matter how demand evolves.
4. Partner concentration risk: J&J controls commercialization, and its dual ownership of the competing modality makes Legend’s strategic options dependent on the partner’s choices.